Biomarkers – Multimedia

Marketa Bockova, Institute of Photonics and Electronics ASCR, speaking at Biodetection & Biosensors 2015

This talk will illustrate, with case studies, how appropriate and timely use of imaging biomarkers can significantly reduce the risk, cost and time of drug development.

Paul Collinson, St Georges Healthcare NHS Trust, speaking at Point of Care Diagnostics 2015

The High Throughput Biomedicine unit at FIMM Technology Centre provides a wide range of biomedical high throughput assays.

This presentation will outline key issues in oncology biomarker testing and describe findings from a study of practices used by National Cancer Institute (NCI) designated cancer centers, the leading U.S. oncology institutions, for testing key biomarkers in three solid tumors - breast, gastroesophageal and non-small cell lung cancers.

Imaging has been at the heart of Medicine for many decades. However, its influence is changing as the need increases not only for diagnosis of disease, but also for quantification of disease extent, identification of suitable candidates for treatment and for testing of both treatment response or assessment of potential side effects for new treatments.

Jeff Cummings presents a worked example of circulating tumour cell enumeration as a prognostic/predictive biomarker in cancer research.

Metabolomics has been successfully applied to identify and validate biomarkers for congestive heart failure. Diagnosis and risk stratification of heart failure (HF) is challenging.

Targeted mass spectrometry, called MRM or SRM, allows for the rapid quantification of hundreds of proteins in a single assay. This tool is very specific, highly quantitative and requires very little sample (e.g. < 5 uL plasma).

Claire Morgan discusses the need to identify a panel of biomarkers that may distinguish indolent cancer from aggressive metastatic disease when used collectively.